Security key
N62509117
NewAmsterdam Pharma Co N.V. - *W EXP 99/99/999 (NAMSW)
CUSIP: N62509117
Q3 2026 13F Holders as of 30 Sep 2026
- Security type / class
- Equity / *W EXP 99/99/999
- Total 13F shares
- 245,000
- Total 13F value
- $3,305,050
- Share change
- 0
- SEC-reported price per share
- $13.49
- Number of holders
- 1
Report period
Q3 2026
Institutions
1
Top holders
1
NAMSW full security history
Ownership snapshot
Full 13F holder table
NewAmsterdam Pharma Co N.V. SEC filings
NewAmsterdam Pharma Co N.V. company facts
Broader feeds
Reporting periods
Holder history for CUSIP N62509117
Recent filing periods:
Ownership snapshot
Top reported holders of NAMSW - NewAmsterdam Pharma Co N.V. - *W EXP 99/99/999 (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Capital World Investors
Disclosed value leader
Frazier Life Sciences Man...
Comparable rows
7/15
Latest evidence
18 Sep 2026
13D/G
13F
3/4/5
Lead comparable stake: 10%
8 rows are not safely comparable across share classes.
13D/G row: Capital World Investors
Showing 1-6 of 15 holder rows.
Quick read
Capital World Investors leads the comparable SEC ownership view at 10%.
7 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Capital World Investors's linked filing trail.
Comparable ownership
Top 5
Capital World Investors
10%
FMR LLC
10%
RA CAPITAL MANAGEMENT, L.P.
9.9%
Frazier Life Sciences X, L.P.
8.7%
Forbion Capital Fund IV Cooperati...
8.3%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Capital World Investors |
13D/G
13F
Company
|
10%
Reported 13D/G
· 29 May 2026
|
$460,111,232
12,188,377 shares
|
+$89,303,892 | 29 May 2026 |
| FMR LLC |
13F
13D/G
Company
|
10%
Reported 13D/G
· 30 Sep 2026
|
$350,411,179
10,339,663 shares
|
— | 30 Jun 2026 |
| RA CAPITAL MANAGEMENT, L.P. |
13F
13D/G
Company
|
9.9%
Reported 13D/G
· 31 Mar 2025
|
$330,779,299
9,883,524 shares
mixed-class rows
|
— | 30 Jun 2026 |
| Frazier Life Sciences X, L.P. |
13D/G
Frazier Life Sciences Public Fund, L.P.
|
8.7%
Reported 13D/G
· 18 Sep 2026
|
$269,987,402
10,424,224 shares
|
+$46,627,382 | 18 Sep 2026 |
| Forbion Capital Fund IV Cooperatief U.A. |
13D/G
ForGrowth NAP B.V.
|
8.3%
Reported 13D/G
· 26 Sep 2025
|
$223,140,090
9,316,914 shares
|
-$30,222,313 | 26 Sep 2025 |
| VIKING GLOBAL INVESTORS LP |
13D/G
13F
Company
|
3.7%
Reported 13D/G
· 31 Dec 2025
|
$144,476,598
4,203,567 shares
|
-$95,375,616 | 31 Dec 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
1
Shares
245,000
Rows available
1
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2026 vs Q2 2026 Across Filers
Q2 2026 holders
9
Q3 2026 holders
1
Holder diff
-8
| Investor | Q2 2026 Shares | Q3 2026 Shares | Share Diff | Share Chg % | Q2 2026 value | Q3 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend